By Ramez N. Eskander, Robert E. Bristow
During this age of complex expertise, there's a major volume of dynamic literature surrounding the analysis and remedy of gynecologic cancers. regardless of this data surplus, residence officials and junior college learning gynecologic oncology point out a necessity for a competent, simply obtainable, streamlined source for daily use. Gynecologic Oncology: A Pocketbook is a collaborative attempt that mixes the views of specialist school and fellows in education within the box of gynecologic oncology. not just is it awfully moveable, however the structure within which the data is gifted (bullet aspect, define, tables and diagrams) makes it possible for fast entry to helpful details and is exclusive among present texts. This specified pocketbook will give you the info had to deal with sufferers with gynecologic malignancies safely and may advertise serious pondering all through treatment.
Read or Download Gynecologic Oncology: A Pocketbook PDF
Best obstetrics & gynecology books
Hypertensive problems stay one the main explanations of maternal and fetal morbidity and loss of life. it's also a number one reason behind preterm start referred to now to be a danger consider distant heart problems. regardless of this the hypertensive problems stay marginally studied and administration is frequently debatable.
Over the last 20 years, the striking advances in imaging ideas, akin to ultrasound and quick or ultra-fast MRI, have ended in the analysis of more and more tumors on the prenatal level. This revised, abundantly illustrated moment variation of Tumors of the Fetus and baby: An Atlas offers an up to date account of the scientific and pathological beneficial properties of neoplastic illness and tumor-like stipulations within the fetus, neonate, and child and discusses significant tumor reports and circumstances from during the international.
16 British experts pool their huge wisdom of spontaneous abortion in a single resource. Their dialogue is at once appropriate to scientific events and is helping establish components of discussion and substitute equipment.
- Gynecologic Imaging
- Prevention and Management of Complications from Gynecologic Surgery, An Issue of Obstetrics and Gynecology Clinics (The Clinics: Internal Medicine)
- First Aid for the Obstetrics and Gynecology Clerkship, Third Edition (First Aid Series)
- Ultrasound in Obstetrics and Gynaecology Book: European Practice in Gynaecology and Obstetrics Series
Extra resources for Gynecologic Oncology: A Pocketbook
2011;5:1–5. 57. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6. 58. Eskander RN, Tewari KS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma— mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol. 2014;132:496–505. 59. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX. Incorporation of bevacizumab in the primary treatment of ovarian cancer.
73. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21. 74. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature. 2005;434:913–7. 75. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A.
7 months, 31 of 32 patients were alive. Only one patient died and it was unrelated to the ovarian disease process. • Due to the low percentage of actively dividing cells that are present in borderline ovarian tumors, these are thought to be relatively resistant to standard cytotoxic agents. • Furthermore, adjuvant chemotherapy in patients with ovarian serous borderline tumors with invasive peritoneal implants showed no improvement in time to recurrence or overall survival. • As noted earlier, even patients with advanced-stage disease can be expected to have excellent overall survival rates.